Abstract
A biotinylated peptide covering a sequence of 21 amino acids (aa) from the erythrocyte binding antigen (EBA-175) of Plasmodium falciparum bound to human glycophorin A, an erythrocyte receptor for merozoites, as demonstrated by enzyme-linked immunosorbent assay (ELISA) and to erythrocytes as demonstrated by flow cytometry analysis. The peptide, EBA(aa1076–96), also bound to desialylated glycophorin A and glycophorin B when tested by ELISA. The peptide blocked parasite multiplication in vitro. The glycophorin A binding sequence was further delineated to a 12-aa sequence, EBA(aa1085–96), by testing the binding of a range of truncated peptides to immobilized glycophorin A. Our data indicate that EBA(aa1085–96) is part of a ligand on the merozoite for binding to erythrocyte receptors. This binding suggests that the EBA(aa1085–96) peptide is involved in a second binding step, independent of sialic acid. Antibody recognition of this peptide sequence may protect against merozoite invasion, but only a small proportion of sera from adults from different areas of malaria transmission showed antibody reactivities to the EBA(aa1076–96) peptide, indicating that this sequence is only weakly immunogenic during P. falciparum infections in humans. However, Tanzanian children with acute clinical malaria showed high immunoglobulin G reactivity to the EBA(aa1076–96) peptide compared to children with asymptomatic P. falciparum infections. The EBA(aa1076–96) peptide sequence from EBA-175 induced antibody formation in mice after conjugation of the peptide with purified protein derivative. These murine sera inhibited EBA(aa1076–96) peptide binding to glycophorin A.
Several Plasmodium falciparum proteins play a role in merozoite invasion of erythrocytes (2, 15). Among these, the proteins that participate in the sequence of events leading to invasion include MSP-1, which possibly mediates initial contact between merozoites and erythrocytes, and EBA-175, a micronemal protein, which binds to erythrocytes and may be involved in junction formation.
EBA-175 may bind to erythrocytes via two mechanisms: an initial binding, which is dependent on sialic acid, and a secondary binding, which is not dependent on sialic acid. A conserved region of 42 aa of EBA-175, EBA-peptide 4(1062–1103), has been implicated in the binding to the erythrocyte (16), although it is not essential for the initial sialic acid-dependent binding (17). We have synthesized peptides from this putative erythrocyte binding region of EBA-175 and used them for identification of the minimum peptide sequence mediating attachment to erythrocytes. This peptide binding is not dependent on sialic acid. We also report that the erythrocyte binding sequence is recognized by IgG antibodies of children with acute malaria but not by IgG antibodies of children with asymptomatic infections nor by IgG antibodies of adults living in regions of malaria transmission. Antibodies to EBA(aa1076–96) can be induced in mice by immunization.
MATERIALS AND METHODS
Abbreviations used in this paper:
aa, amino acids; EBA, erythrocyte binding antigen; ELISA, enzyme-linked immunosorbent assay; Fmoc, fluorenylmethoxycarbonyl; HOBt, hydroxybenzotriazol; HPLC, high-pressure liquid chromatography; Ig, immunoglobulin; MBHA, methylbenzhydrylamine; MSP-1, merozoite surface protein 1; NMM, N-methylmorpholine; NMP, N-methylpyrrolidone; OD, optical density; PBS, phosphate-buffered saline; PPD, purified protein derivative; SD, standard deviation; TBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate.
Synthetic peptides.
The sequences of the synthetic peptides synthesized are as follows. PfMSP-1 peptide has the sequence YSLFQKEKMVL, a sequence included in the malaria vaccine SPf66. The EBA-175 peptides contain overlapping amino acid sequences from the EBA-175 region 1062 to 1104: EBA(aa1062–86) peptide, SNNEYKVNEREDERTLTKEYEDIVL; EBA(aa1076–96) peptide, TLTKEYEDIVLKSHMNRESDD; EBA(aa1086–1104) peptide, LKSHMNRESDDGELYDENS. The following truncated EBA(aa1076–96) peptide variants were produced: EBA(aa1077–96), LTKEYEDIVLKSHMNRESDD; EBA(aa1078–96), TK EYEDIVLKSHMNRESDD; EBA(aa1079–96), KEYEDIVLKSHMNRESDD; EBA(aa1080–96), EYEDIVLKSHMNRESDD; EBA(aa1081–96), YEDIVLKSHMNRESDD; EBA(aa1082–96), EDIVLKSHMNRESDD; EBA(aa1083–96), DIVLKSHMNRESDD; EBA(aa1084–96), IVLKSHMNRESDD; EBA(aa1085–96), VLKSHMNRESDD; EBA(aa1086–96), LKSHMNRESDD; and EBA(aa1087–96), KSHMNRESDD. The EBA-175 peptides covered a sequence reported to be involved in erythrocyte binding, while the PfMSP-1 peptide is included in the SPf66 vaccine (14) and has been reported to bind to erythrocytes (1).
Peptides were synthesized automatically on MBHA resins (Novabiochem; 0.1 to 0.5 meq/g) with a Rink− [4(2′,4′-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido] linker. Automatic syntheses were performed on a Mark-III machine under continuous-flow conditions with conductivity monitoring (Schafer-N). Amino acids were aminoprotected with Fmoc and activated for 10 min just before coupling by using the free acids with TBTU-HOBt-NMM (1:1:2 equivalents compared to amino acid; NMM used at 0.4 M in NMP). The peptides were biotinylated, after removal of the last Fmoc group, by using biotin-TBTU-HOBt-NMM in NMP with the molecular amounts given above until a negative ninhydrin test (9) was obtained.
The finished peptide was cleaved by treatment of the solid-phase-coupled peptide with 95% trifluoroacetic acid in water (5 ml) for 100 mg of resin. Incubation took place in a closed container with shaking at room temperature for 30 min; then another 5 ml was added, and the mixture was incubated for 30 min. This was repeated a total of six times. Then the resin was filtered off and the liberated peptide was precipitated from the trifluoroacetic acid-water filtrate with cold diethyl ether, filtered through a 0.45-μm-pore-size filter, dissolved in water, freeze-dried, and analyzed by C18 reverse-phase HPLC with diode-array detection by using Varian Star Chromatography software data handling for calculation of within-peak purity factors and total purity at 220 nm. To reproduce the results, an additional batch of peptides was synthesized in the same way. The peptides were subjected to matrix-assisted laser-desorption ionization time-of-flight mass spectrometry on a Fisons VG Tofspec E apparatus with associated hardware, with α-cyano-4-hydroxycinnamic acid as the matrix to confirm masses. Peptide concentrations were determined by quantitative HPLC with full-length EBA(aa1076–96) peptide as the standard.
Peptide binding to glycophorin in ELISAs.
Glycophorin A, glycophorin B, and desialylated glycophorin A were purified as previously described (11, 20). Another batch of glycophorin A was purchased from Sigma (St. Louis, Mo.). Glycophorin preparations (10 μg/ml) were coated in 100 mM NaHCO3 (pH 9.6) on Maxisorp microtiter plates (Nunc, Roskilde, Denmark). All coatings were performed overnight at 4°C. The wells were washed four times in 0.5 M NaCl–3 mM KCl–1 mM KH2PO4–8 mM Na2HPO4–1% Triton X-100. This washing procedure was done after each of the following incubation steps: (i) biotinylated peptides in twofold dilution series (stock 2 mg/ml) diluted in incubation buffer (washing buffer plus 15 mM bovine serum albumin [pH 7.2]) were incubated overnight at 37°C; (ii) 100 μl of streptavidin peroxidase (DAKO) diluted in incubation buffer was added per well at room temperature for 1 h. Enzyme activities were quantitated after addition to each well of 100 μl of 0.67-mg/ml 1,2-phenyldiamine hydrochloride (DAKO) dissolved in 100 mM citric acid-phosphate buffer (pH 5.0) containing 0.015% (vol/vol) H2O2. The reactions were stopped by adding 50 μl of 2.5 M H2SO4 per well, and the OD values were measured in an ELISA scanner at 495 nm. All tests were done in duplicate.
In some experiments, P. falciparum culture supernatants with native EBA-175 (19) were mixed with the biotinylated EBA(aa1076–96) peptide to test the ability of EBA-175 to block peptide binding to glycophorin A.
In some experiments, mouse and human sera were mixed with the biotinylated EBA(aa1076–96) peptide to test the ability of the sera to block peptide binding to glycophorin A.
Flow cytometric analysis of peptide binding to erythrocytes.
Erythrocytes were washed three times in 10 volumes of PBS each time. Biotinylated peptides were resuspended in PBS and incubated in 50 μl (1 volume) with 106 erythrocytes per reaction for 1 h at room temperature and then washed three times in 20 volumes of PBS. Quantum red-conjugated streptavidin (Sigma, St. Louis, Mo.) and Ig (Miles Inc., Elkhart, Ind.) at 2 mg/ml as blocker was added, and the mixture was incubated for 15 min at room temperature. The samples were analyzed by flow cytometry after being washed three times with 20 volumes of PBS.
Effect on parasite growth in vitro.
P. falciparum isolate 3D7 was kept in continuous cultures as described by Jepsen and Andersen (6), with RPMI 1640 supplemented with 21 mM sodium bicarbonate, 25 mM HEPES buffer and 10% human serum. The parasites were grown in 4% (vol/vol) group 0 positive human erythrocytes.
The inhibitory activity of the synthetic peptides was measured in asynchronous cultures of P. falciparum by a microdilution assay as described by Desjardins et al. (3). Initial parasitemia was 5%, the erythrocyte concentration was 5%, and the incubation period was 48 h. All peptides were diluted in complete culture medium to the desired concentrations just before use. Growth of the malaria parasites was measured by the incorporation of [3H]hypoxanthine.
Immunization of mice.
EBA(aa1076–96) peptide (1.2 mg) was conjugated to 1 mg of PPD of mycobacteria (5 mol of peptide per mol of PPD) with equal volumes of 0.2% glutaraldehyde diluted in 0.1 M phosphate buffer (pH 7.5).
Mycobacterium bovis BCG-primed mice (CF1 × BALB/c)F1 were immunized with peptides conjugated to PPD or with PPD alone. The mice were immunized three times, with 21 days between the first and second immunizations and 28 days between the second and third immunizations. The mice were immunized subcutaneously with 35 μg of peptide or intraperitoneally with 16 μg of peptide.
Human sera.
Sera were collected from three different regions of endemic malaria infection. (i) Sera were collected in 1984 from 15- to 67-year-old donors from villages in a region of holoendemic infection in Irian Jaya, Indonesia. At the time of serum collection, the principal infections were with P. falciparum and P. malariae. Splenomegaly was common in the study population. (ii) Sera were collected in 1984 during the medium transmission season from 19- to 28-year old soldiers in a region of hyperendemic infection in Juba at the White Nile river in Sudan. The principal infection was with P. falciparum. (iii) Sera were collected in 1986 from 15- to 80-year-old donors in a region of holoendemic infection in Enugu near Nyssuka, Nigeria. The principal infection was with P. falciparum.
All the donors tested were selected for their high antibody reactivity against malaria parasites when measured by precipitating antibodies against a mixture of exoantigens and as ELISA antibody reactivity to recombinant rhoptry-associated protein 1 (RAP-1) (5).
Sera were also collected in 1993 from children 1 to 4 years old living at Magoda village in the Muheza district (northeastern Tanzania), an area of holoendemic malaria infection. The majority of children had asymptomatic P. falciparum infections with low levels of parasitemia. Seven children with levels of parasitemia exceeding 5,000/μl and temperatures exceeding 37.5°C and/or C-reactive protein concentrations exceeding 8 μg/ml were categorized as having clinical malaria and were treated with chloroquine. Fingerprick blood samples were collected from the children, and serum was obtained. Details of this study are described elsewhere (3a).
Control sera were obtained from adult Danish donors in 1991. All sera used in the study were stored at −20°C.
Antibody reactivity with native proteins and synthetic peptides in ELISA.
Peptides conjugated to ovalbumin (1 μg/ml) (to test mice sera) or incorporated into immunostimulating complexes (1 μg/ml) (to test human sera) were coated in 100 mM NaHCO3 (pH 9.6) on Maxisorp microtiter plates (Nunc) overnight at 4°C. Washing, incubation, substrate diluents, and OD measurements were as described for the glycophorin solid-phase enzyme assay. The washing procedure was done after each of the following incubation steps: (i) mouse or human sera made to 1% (vol/vol) in incubation buffer were incubated for 1 h at room temperature; (ii) 100 μl of peroxidase-conjugated rabbit anti-human IgG or biotinylated rabbit anti-mouse IgG antibodies (Amersham) per well diluted in incubation buffer was incubated for 1 h at room temperature, and (iii) 100 μl of streptavidin-conjugated peroxidase (DAKO) diluted in incubation buffer was added per well at room temperature for 1 h. All tests were done in duplicate.
Statistical methods.
The data obtained with serum samples collected from Tanzanian children were analyzed by the Mann-Whitney rank sum test for intergroup comparisons because of the skewed data distributions. All P values less than 0.05 were considered significant. The calculations were performed with Sigmastat (Jandel Scientific, San Rafael, Calif.) software.
RESULTS
Evaluation of synthetic peptides.
Peptide purities were ascertained through HPLC purification and within-peak evaluation with diode array detection. The peaks were >95% pure, and all had good purity factors. Mass spectrometry confirmed the predicted molecular masses within 3 Da.
EBA peptide binding to erythrocytes.
Biotinylated EBA(aa1076–96) peptide showed a strong concentration-dependent binding to glycophorin A immobilized on polystyrene plates compared to biotinylated peptides EBA(aa1086–1104) and EBA(aa1062–86) as well as the PfMSP-1 peptide (Fig. 1a). Similar binding of biotinylated EBA(1076–96) peptide to human erythrocyte ghosts was detectable in four different experiments (data not shown). Saturation of peptide binding to glycophorin A was obtained with concentrations exceeding 8 μM biotinylated EBA(aa1076–96) peptide. Figure 1b shows that native EBA-175 inhibited the binding of biotinylated EBA(aa1076–96) peptide to glycophorin A; 9% of the peptide binding was not blocked by native EBA-175 and appears to be nonspecific background binding. To test the specificity of the peptide binding to glycophorin A, we also tested peptide binding to desialylated glycophorin A and to glycophorin B immobilized on polystyrene plates in addition to glycophorin A. EBA(aa1076–96) peptide showed similar binding to all the glycophorin preparations tested (data not shown), indicating that peptide binding is not specific for glycophorin A and is not dependent on sialic acid.
FIG. 1.
Binding of biotinylated peptides to glycophorin A. (a) Binding of biotinylated peptides to ELISA wells coated with glycophorin A protein. ▵, PfMSP-1 peptide; ▿, EBA(aa1062–86) peptide; ○, EBA(aa1076–96) peptide; □, EBA(aa1086–1104) peptide. Background ODs were less than 200. The mean and SD for four experiments are shown. (b) Blocking of biotinylated EBA(aa1076–96) to polystyrene plate wells coated with glycophorin A by serial dilutions of native EBA-175. The mean and SD for three experiments are shown.
To further identify the glycophorin binding sequence, we produced 11 truncated EBA(aa1076–96) peptide variants containing between 20 and 10 aa (see Materials and Methods). Biotinylated truncated peptides EBA(aa1077–96) to EBA(aa1085–96) showed strong binding to glycophorin A, while truncated peptides (EBA(aa1086–96) and EBA(aa1087–96) showed no or little binding activity. For simplicity, Fig. 2 shows the results obtained with peptides EBA(aa1085–96), EBA(aa1086–96), and EBA(aa1087–96) only. Our data indicate that the peptide sequence VLKSHMNRESDD encompasses the glycophorin A binding sequence.
FIG. 2.
Binding of biotinylated truncated EBA(aa1076–96) variants to polystyrene wells coated with glycophorin A protein. ○, EBA(aa1076–96); ▵, EBA(aa1087–96); □, EBA(aa1086–96); ◊, EBA(aa1085–96). The mean and SD for three experiments are shown.
EBA peptide binding to erythrocytes in flow cytometry analysis.
EBA(aa1076–96) peptide bound to erythrocytes (Fig. 3). Maximum binding was 85% of the erythrocytes at peptide concentrations above 1 mg/ml. The binding decreased to 65% at peptide concentrations of 0.5 mg/ml. EBA(aa1086–1104) peptide did not bind to erythrocytes (data not shown).
FIG. 3.
Flow cytometry analysis of peptide binding to erythrocytes. (a) Binding of biotinylated EBA(aa1076–96) (2 mg/ml); (b) binding of control secondary antibody alone.
Inhibition of parasite multiplication in vitro by EBA peptide.
EBA(aa1076–96) peptide showed a concentration-dependent blocking of parasite growth in vitro (Fig. 4). At 8 μM EBA(aa1076–96), peptide almost completely blocked parasite multiplication. Peptide EBA(aa1086–1104) showed no blocking of parasite multiplication.
FIG. 4.
Blocking of parasite multiplication in vitro by EBA(aa1076–96) (○) and EBA(aa1086–1104) (□). The mean percent inhibition and SD for four independent experiments are shown.
Reactivities of human sera to EBA peptides in ELISA.
Serum reactivity with peptide was defined as being positive if the OD of the serum sample was higher than the mean plus 3 times the standard deviation of OD values obtained with 10 Danish controls. When tested at a dilution of 1:100, only a proportion of the sera tested reacted with EBA(aa1076–96) peptide. Of 44 tested Sudanese serum samples, 5 were reactive with the peptide, whereas 6 of 33 Indonesian sera and 2 of 20 Nigerian sera were reactive.
Seven Tanzanian children with clinical episodes of malaria had higher reactivities of IgG in serum to EBA(aa1076–96) peptide (median, 2.11 ELISA units; 25 and 75% quartiles, 1.09 and 4.06 ELISA units) than did 101 children with asymptomatic P. falciparum infections (median, 1.00 ELISA unit; 25 and 75% quartiles, 0.67 and 1.51 ELISA units) (P = 0.02).
Immunization of mice with EBA peptides.
BCG-primed mice immunized with PPD-conjugated EBA(aa1076–96) peptide in the absence of Freund’s complete adjuvant produced antibodies against this peptide (Fig. 5). The antibody reactivity increased with each immunization, and intraperitoneal immunization was superior to subcutaneous immunization. Sera from mice immunized three times inhibited EBA(aa1076–96) peptide binding to glycophorin A in the solid-phase assay (Table 1), while sera from the Indonesian, Nigerian, and Sudanese donors did not block peptide binding to glycophorin A whether they were reactive with the EBA peptide or not.
FIG. 5.
ELISA for murine IgG reactivities to EBA(aa1076–96). Results of duplicate tests on four mice in each group are shown. •, peptide-PPD intraperitoneal immunization; ○, peptide-PPD subcutaneous immunization; ■, PPD control intraperitoneal immunization; □, PPD control subcutaneous immunization.
TABLE 1.
Percent inhibition of EBA(aa1076–96) peptide (20 μg/ml) binding to glycophorin A by sera from mice immunized with EBA(aa1076–96) peptide conjugated to PPD
| Serum source | % Inhibition of EBA(aa1076–96) at serum dilution ofa:
|
|
|---|---|---|
| 1:10 | 1:50 | |
| Mice after first immunization | 16.8 (4.0) | 6.6 (4.5) |
| Mice after second immunization | 26.0 (12.5) | 23.0 (3.8) |
| Mice after third immunization | 56.7 (13.6) | 40.0 (5.5) |
Mean percent inhibition and SD for three different experiments are shown.
DISCUSSION
The main finding in this study is the identification of a 12-aa peptide sequence of the malaria vaccine candidate EBA-175 which binds to glycophorin and may be involved in the invasion process of merozoites into erythrocytes. The 12-aa sequence is contained within a 43-aa conserved sequence originally identified as the putative erythrocyte binding region, since rabbit antisera against this region block parasite multiplication and EBA-175 binding to erythrocytes (13, 19).
When merozoites attach to and invade erythrocytes, a sequence of events takes place in which the first step is a lectin-like binding of merozoites to erythrocytes followed by reorientation of merozoites, bringing the apical pole in contact with the erythrocyte and leading to junction formation (7). Two different proteins, EBA-175 and MSP-1, have been implicated in mediating the initial binding of merozoites to the erythrocyte. EBA-175 is a protein, located in micronemes (18) and released into culture supernatants (2), that binds N-acetylneuraminic acid, α2-3-Gal determinants on O-linked carbohydrates of glycophorin A on the erythrocyte membrane (12). EBA-175 may mediate a two-step invasion procedure, an initial lectin-like binding followed by a second, possibly hydrophobic binding, triggering internalization of the merozoite. A cysteine-rich region of EBA, the F2 fragment, mediates the lectin-like binding to glycophorin A (17), while a 65-kDa processing fragment of EBA was reported to bind to an erythrocyte determinant in a sialic acid-independent manner (8). This fragment does not contain the 43-aa sequence, and the relative role of the 65-kDa fragment and the fragment containing the 43-aa sequence in any secondary binding steps remains unknown.
To further characterize the erythrocyte binding sequence, we synthesized three overlapping peptides covering the 43-aa region. We showed that EBA(aa1076–96) bound strongly to erythrocytes and more specifically to glycophorin A when tested in a solid phase binding assay. We also showed that soluble EBA(aa1076–96) bound to intact erythrocytes. The binding of EBA(aa1076–96) to erythrocytes does not appear to be dependent on sialic acid, since the peptide bound to desialylated glycophorin A. We hypothesized that EBA(aa1076–96) is involved in the second step of a two-step binding process which may resemble HIV-1 gp160 binding to lymphocytes, where both gp120 and gp41 processing fragments remain attached to the lymphocytes through different binding sites. Virus entry is facilitated by an envelope-mediated fusion of the viral and target cell membranes. After formation of gp120 binding to CD4 as well as processing of gp160 to gp120 and gp41 fragments, the mobility of the envelope protein is afforded by the noncovalent nature of the gp120-gp41 bond, which may allow efficient exposure of the lymphocyte membrane to the hydrophobic gp41 regions that mediate the fusion process (10). Multiple regions of gp41 are involved in the invasion process by interaction with CD4 and other cellular receptors, as well as being involved in conformational changes of gp41 (21). Likewise, we hypothesized that the initial and specific cystein-rich fragment binding to sialic acid on glycophorin A induces a conformational change in EBA-175 which may expose the EBA(aa1076–96) peptide fragment to subsequent erythrocyte binding. Both the EBA(aa1076–96) peptide-containing fragment and the 65-kDa fragment reported by Kain et al. (8) may participate in the secondary binding to the erythrocyte, which is independent of sialic acid and may be more nonspecific. The two regions play different roles, since an EBA-175 peptide of 42 aa comprising the EBA(aa1076–96) peptide blocks binding of the full-length EBA-175 whereas a peptide from the 65-kDa EBA-175 fragment blocks the binding only of the 65-kDa fragment but not of full-length EBA-175 (8, 19). To further characterize the binding sequence of the EBA(aa1076–96) peptide, we showed that the amino acid sequence, VLKSHMNRESDD, at positions 1085 to 1096 of EBA-175 contained the binding sequence when the binding of 11 truncated peptide variants, EBA(aa1077–96) to EBA(aa1087–96), to glycophorin A immobilized on polystyrene plates was tested. To substantiate the evidence that EBA(aa1076–96) contains the erythrocyte binding site, we tested the ability of EBA(aa1076–96) peptide to block parasite multiplication. The peptide showed a strong parasite-blocking activity. EBA(aa1076–96) peptide may compete with merozoites for binding to erythrocytes.
Antibodies against erythrocyte binding domains of EBA-175 may block the ability of merozoites to invade erythrocytes. Such antibodies may be responsible for the achievement of clinical immunity against malaria. The immune response to EBA-175 among humans living in regions of endemic infection remains poorly characterized. However, lymphocyte proliferation responses to EBA(aa1086–1104) but not to EBA(aa1076–96) among Ghanaian donors have been reported (4). None of the peptides were recognized by IgG antibodies from the Ghanaian donors. In this study, we selected sera from donors living in Indonesia, Nigeria, and Sudan with long exposure to malaria; the sera were highly reactive with a recombinant RAP-1 (5). The majority of these sera had low or negliable IgG reactivity to the EBA(aa1076–96) peptide. However, sera from young Tanzanian children with clinical malaria had high IgG reactivities to EBA(aa1076–96), and their reactivities were higher than the IgG reactivities of sera collected from children with asymptomatic infections. Whether these antibodies play a harmful role needs further investigations. Our data indicate that there is a high antigenic threshold for induction of antibody reactivities against the peptide and that infections do not induce a sustained antibody response against the peptide. We then investigated whether antibodies against the EBA(aa1076–96) peptide could be induced by vaccination of mice. We found that PPD-conjugated peptide induced the formation of antibodies against the peptide and that these murine sera inhibited EBA(aa1076–96) peptide binding to glycophorin A, in contrast to human sera. In conclusion, we have identified a short amino acid sequence of EBA-175 capable of binding to glycophorin A of erythrocytes. The peptide binding does not depend on sialic acid, but it may be involved in a second, relatively nonspecific binding step of EBA-175 during merozoite invasion. The peptide blocks parasite multiplication. Finally, the erythrocyte binding sequence appears to induce only an unstable antibody response during P. falciparum infections of humans, but antibodies against the peptide can be induced by vaccination.
ACKNOWLEDGMENTS
Jimmy Weng, Gitte Stoltenberg, Gitte Juhl Funck, and Dorthe Kolding are thanked for excellent technical assistance.
REFERENCES
- 1.Calvo M, Guzman F, Perez E, Segura C H, Molano A, Patarroyo M E. Specific interactions of synthetic peptides derived from P. falciparum merozoite proteins with human red blood cells. Peptide Res. 1991;4:324–332. [PubMed] [Google Scholar]
- 2.Camus D, Hadley T J. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science. 1985;230:553–555. doi: 10.1126/science.3901257. [DOI] [PubMed] [Google Scholar]
- 3.Desjardins R E, Canfield C J, Haynes J D, Chulay J D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrobial Agents Chemother. 1979;16:710–718. doi: 10.1128/aac.16.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3a.Jakobsen, P. H. Unpublished data.
- 4.Jakobsen P H, Hviid L, Theander T G, Afare E A, Ridley R G, Heegaard P M H, Stuber D, Dalsgaard K, Nkrumah F K. Specific T-cell recognition of the merozoite proteins rhoptry-associated protein 1 and erythrocyte-binding antigen 1 of Plasmodium falciparum. Infect Immun. 1993;61:268–273. doi: 10.1128/iai.61.1.268-273.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Jakobsen P H, Kurtzhals J A L, Riley E M, Hviid L, Theander T G, Morris-Jones S, Jensen J B, Bayoumi R A L, Ridley R G, Greenwood B M. Antibody responses to rhoptry-associated protein 1 (RAP-1) of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Parasite Immunol. 1997;19:387–393. doi: 10.1046/j.1365-3024.1997.d01-234.x. [DOI] [PubMed] [Google Scholar]
- 6.Jepsen S, Andersen B J. Immunosorbent isolation of antigens from the culture medium of in vitro cultivated Plasmodium falciparum. Acta Pathol Microbiol Scand Sect C. 1981;89:99–103. doi: 10.1111/j.1699-0463.1981.tb02671.x. [DOI] [PubMed] [Google Scholar]
- 7.Jungery M, Pasvol G, Newbold C I, Weatherall D J. A lectin-like receptor is involved in invasion of erythrocytes by Plasmodium falciparum. Proc Natl Acad Sci USA. 1983;80:1018–1022. doi: 10.1073/pnas.80.4.1018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Kain K C, Orlandi P A, Haynes J D, Sim B K L, Lanar D E. Evidence for two-stage binding by the 175-kD erythrocyte binding antigen of Plasmodium falciparum. J Exp Med. 1993;178:1497–1505. doi: 10.1084/jem.178.5.1497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kaiser R, Colescott R L, Bossinger C D, Cook P I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970;34:595–598. doi: 10.1016/0003-2697(70)90146-6. [DOI] [PubMed] [Google Scholar]
- 10.Kowalski M, Potz J, Basiripour L, Dorfman T, Goh W C, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 1987;237:1351–1355. doi: 10.1126/science.3629244. [DOI] [PubMed] [Google Scholar]
- 11.Lisowska E, Messeter L, Duk M, Czerwinski M, Lundblad A. Monoclonal anti-glycophorin A antibody recognizing the blood group M determinant: studies on the subspecificity. Mol Immunol. 1987;24:605–613. doi: 10.1016/0161-5890(87)90041-1. [DOI] [PubMed] [Google Scholar]
- 12.Orlandi P A, Klotz F W, Haynes J D. A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha2-3)Gal-sequences of glycophorin A. J Cell Biol. 1992;116:901–909. doi: 10.1083/jcb.116.4.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Orlandi P A, Sim B K L, Chulay J D, Haynes J D. Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasitol. 1990;40:285–294. doi: 10.1016/0166-6851(90)90050-v. [DOI] [PubMed] [Google Scholar]
- 14.Patarroyo M E, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo L A, Ponton G, Trujillo G. A synthetic vaccine protects humans against challenge with asexual blood stages of P. falciparum malaria. Nature. 1988;332:158–161. doi: 10.1038/332158a0. [DOI] [PubMed] [Google Scholar]
- 15.Perkins M E, Rocco L J. Sialic acid-dependent binding of Plasmodium falciparum merozoite surface antigen, Pf200, to human erythrocytes. J Immunol. 1988;141:3190–3196. [PubMed] [Google Scholar]
- 16.Sim B K L. Sequence conservation of a functional domain of erythrocyte binding antigen 175 in Plasmodium falciparum. Mol Biochem Parasitol. 1990;41:293–296. doi: 10.1016/0166-6851(90)90193-p. [DOI] [PubMed] [Google Scholar]
- 17.Sim B K L, Chitnis C E, Wasniowska K, Hadley T J, Miller L H. Receptor and ligand domains for invasion of Plasmodium falciparum. Science. 1994;264:1941–1944. doi: 10.1126/science.8009226. [DOI] [PubMed] [Google Scholar]
- 18.Sim B K L, Toyoshima T, Haynes J D, Aikawa M. Localization of the 175-kilodalton erythrocyte binding antigen in micronemes of Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1992;51:157–160. doi: 10.1016/0166-6851(92)90211-2. [DOI] [PubMed] [Google Scholar]
- 19.Sim B K L, Carter J M, Deal C D, Holland C, Haynes J D, Gross M. Plasmodium falciparum: further characterization of a functionally active region of the merozoite invasion ligand EBA-15. Exp Parasitol. 1994;78:259–268. doi: 10.1006/expr.1994.1027. [DOI] [PubMed] [Google Scholar]
- 20.Wasniowska K, Reichert C M, McGinniss M H, Schroer K R, Zopf D, Lisowska L, Messeter L, Lundblad A. Two monoclonal antibodies highly specific for the blood group N determinant. Glycoconjugate J. 1985;2:163–176. [Google Scholar]
- 21.Wild C T, Shugars D C, Greenwell T K, McDanal C B, Matthews T J. Peptides corresponding to a predictive alpha-helix domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA. 1994;91:9770–9774. doi: 10.1073/pnas.91.21.9770. [DOI] [PMC free article] [PubMed] [Google Scholar]